Mapping genetic factors in high-grade glioma patients
- PMID: 27668860
- DOI: 10.1016/j.clineuro.2016.09.012
Mapping genetic factors in high-grade glioma patients
Abstract
Background: Tumor location, which serves as a prognostic factor for high-grade gliomas, may reflect the molecular and genetic phenotype of tumor initiate cells and thus predict tumor origin. Therefore, the purpose of this study was to combine radiographic atlases and tumor biomarkers through a voxel-based neuroimaging approach.
Methods: Preoperative MRIs were collected from 65 newly diagnosed patients with histologically confirmed high-grades gliomas. These samples were analyzed for TP53 mutations and MMP-9.PTEN, MGMT, EGFR and IDH1 statuses using a statistical voxel-based lesion-symptom mapping (VLSM) method, which correlates the anatomical location of HGGs with their molecular profile.
Results: VLSM analysis identified P53, Wild-type IDH and EGFR overexpression mutations in the white matter of the periventricular region in the left hemisphere, which can be predicted by a short overall survival from the time of diagnosis. The lack of MGMT promoter methylation deep in the right frontal lobe region indicates a poor prognosis.
Conclusions: Our study demonstrates that different molecular phenotypes are related to specific brain regions. In addition, the structural MRI and genetic profile-based analysis of brain regions associated with survival-associated factors could be used in planning glioma operations and clinical survival predictions.
Keywords: Genetic factors; Glioma; Mapping; VLSM approach.
Copyright © 2016 Elsevier B.V. All rights reserved.
Similar articles
-
Mapping seizure foci and tumor genetic factors in glioma associated seizure patients.J Neurosurg Sci. 2020 Oct;64(5):456-463. doi: 10.23736/S0390-5616.17.04015-2. Epub 2017 May 11. J Neurosurg Sci. 2020. PMID: 28497669
-
Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma.Neuro Oncol. 2018 Oct 9;20(11):1517-1524. doi: 10.1093/neuonc/noy134. Neuro Oncol. 2018. PMID: 30107597 Free PMC article.
-
PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.Acta Neuropathol Commun. 2015 Dec 23;3:88. doi: 10.1186/s40478-015-0265-4. Acta Neuropathol Commun. 2015. PMID: 26699864 Free PMC article.
-
O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.Neurosurgery. 2010 Dec;67(6):1681-91. doi: 10.1227/NEU.0b013e3181f743f5. Neurosurgery. 2010. PMID: 21107199 Review.
-
Input of molecular analysis in medical management of primary brain tumor patients.Rev Neurol (Paris). 2015 Jun-Jul;171(6-7):457-65. doi: 10.1016/j.neurol.2015.04.002. Epub 2015 May 27. Rev Neurol (Paris). 2015. PMID: 26026669 Review.
Cited by
-
Analysis of morphological characteristics of IDH-mutant/wildtype brain tumors using whole-lesion phenotype analysis.Neurooncol Adv. 2021 Jun 24;3(1):vdab088. doi: 10.1093/noajnl/vdab088. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34409295 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous